INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study
ReutersJun 30, 2025 11:33 AM
June 30 (Reuters) - INmune Bio INMB.O said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its shares plunging nearly 59% in premarket trading.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
This Is Why I’m Buying Taiwan Semiconductor Stock in 2026
TradingKey - Taiwan Semiconductor Manufacturing (TSM) is part of a rapidly growing sector in AI.TradingKey
17 hours ago
January CPI Revives Rate-Cut Hopes; Gold and Silver Rebound, But Is the Bull Run Intact?
TradingKey - During Friday's US session, spot gold surged back above $5,000 to close at $5,043, while silver resumed its rally, breaking through the $75 mark to peak near $79 before closing at $77.43. This movement was primarily driven by data from the U.S. Bureau of Labor Statistics that significanTradingKey
21 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to maTradingKey
Thu, Feb 12
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
Thu, Feb 12
